In HNPGLs, Chromogranin A correctly predicts the result of paraganglioma surveillance more often in patients with SDHB compared with those with SDHD (77% vs. 22%, p  =  0.003) and has less added benefit to standard surveillance [34]. This evidence concerns the gene SDHB and paraganglioma.